ERBB2 and breast carcinoma: A phase II clinical trial is currently underway evaluating ZW25 in combination with palbociclib and fulvestrant, with the goal of finding another chemotherapy-free option for patients with advanced HR + /HER2 + breast cancer (NCT04224272).